BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the grant of a US patent protecting its product Sitavig®. This patent covers the Sitavig® tablet, its manufacturing process and its application for the treatment of recurrent labial herpes until 2027.
BioAlliance Pharma has conceived and developed Sitavig® (mucoadhesive tablet containing acyclovir) for the treatment of labial herpes in immunocompetent patients presenting more than 4 episodes a year. Sitavig® is an innovative mucoadhesive tablet to apply to the upper gum, allowing the delivery of very high concentrations of the active ingredient at the site of herpes infection, thus with a reinforced profile of efficacy.
“After the grant of a patent for Sitavig® in Europe and in major Asian territories, this US grant gives BioAlliance a worldwide protection for its product”, declares Aude Michel, Vice President, Licensing and Legal Affairs, and European Patent Attorney of BioAlliance Pharma.
“We have obtained the receivability of Sitavig® US registration file last May from the FDA (Food and Drug Administration). This strong US patent protection allows its commercialization in the best conditions, reinforcing the value of this asset”, added Judith Greciet, CEO of BioAlliance Pharma. “After a first license agreement with Teva for Israel and with a sales potential from $120 to $150 million, this product is becoming a suitable candidate to a license agreement, particularly in the United States”.